Loss of Astrocytic Domain Organization in the Epileptic Brain. Oberheim NA, Tian GF, Han X, Peng W, Takano T, Ransom B, Nedergaard M. J Neurosci 2008;28(13):3264-3276. Gliosis is a pathological hallmark of posttraumatic epileptic foci, but little is known about these reactive astrocytes beyond their high glial fibrillary acidic protein (GFAP) expression. Using diolistic labeling, we show that cortical astrocytes lost their nonoverlapping domain organization in three mouse models of epilepsy: posttraumatic injury, genetic susceptibility, and systemic kainate exposure. Neighboring astrocytes in epileptic mice showed a 10-fold increase in overlap of processes. Concurrently, spine density was increased on dendrites of excitatory neurons. Suppression of seizures by the common antiepileptic, valproate, reduced the overlap of astrocytic processes. Astrocytic domain organization was also preserved in APP transgenic mice expressing a mutant variant of human amyloid precursor protein despite a marked upregulation of GFAP. Our data suggest that loss of astrocytic domains was not universally associated with gliosis, but restricted to seizure pathologies. Reorganization of astrocytes may, in concert with dendritic sprouting and new synapse formation, form the structural basis for recurrent excitation in the epileptic brain.
Astroglial Metabolic Networks Sustain Hippocampal Synaptic Transmission. Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C. Science 2008;322(5907):1551-1555. Astrocytes provide metabolic substrates to neurons in an activitydependent manner. However, the molecular mechanisms involved in this function, as well as its role in synaptic transmission, remain unclear. Here, we show that the gap-junction subunit proteins connexin 43 and 30 allow intercellular trafficking of glucose and its metabolites through astroglial networks. This trafficking is regulated by glutamatergic synaptic activity mediated by AMPA receptors.
In the absence of extracellular glucose, the delivery of glucose or lactate to astrocytes sustains glutamatergic synaptic transmission and epileptiform activity only when they are connected by gap junctions. These results indicate that astroglial gap junctions provide an activity-dependent intercellular pathway for the delivery of energetic metabolites from blood vessels to distal neurons.
COMMENTARY
I n astronomy, the collision of two stars, once believed to be extremely rare, recently has been recognized to be a common, yet spectacular event that results in explosions of colossal magnitude. In neuroscience, the star-like cell, the astrocyte, increasingly has been recognized as having a critical role in normal brain function and neurological disorders, including epilepsy. Similar to stars colliding, it may be the collective interactions of astrocytes within networks-more than the properties of individual astrocytes-that promote explosive electrical discharges of seizures in the brain.
Astrocytes were traditionally viewed as uninteresting, passive brain cells with primarily housekeeping functions, such as structural integrity and metabolic maintenance. However, recent research clearly demonstrates that astrocytes have an impressive diversity of functions and play active, central roles in brain physiology (1) . For example, astrocytes regulate brain excitability by controlling extracellular neurotransmitter and ion levels through specific transporters and pumps. Furthermore, in the so-called tripartite synapse, astrocytes directly participate in brain signaling by responding to neurotransmitters through discrete astrocyte receptor sites and, in turn, modulating neurons and other astrocytes by releasing their own gliotransmitters (2) .
Given the newly recognized roles of astrocytes in brain physiology under normal conditions, it is not surprising that astrocyte dysfunction increasingly is implicated in contributing to epileptogenesis under pathological conditions (3, 4) . Impairment of various astrocyte membrane proteins, including glutamate transporters, potassium channels, and water-permeable aquaporins, may lead to neuronal hyperexcitability and seizures via dysregulation of extracellular glutamate, potassium, or osmotic homeostasis, respectively. Glutamate released from astrocytes may trigger paroxysmal epileptiform discharges in neurons (5) . Furthermore, reactive gliosis, which is a stereotypic morphological and biochemical conversion of astrocytes into an abnormally activated state, occurs commonly in the context of brain injuries and neurodegenerative disorders (6, 7) . While reactive gliosis is often viewed as a beneficial, compensatory response to brain injury, some of these functional alterations likely have detrimental consequences that predispose the patient to developing epilepsy.
Although isolated cellular and molecular alterations in individual astrocytes can promote epileptogenesis, the physiological and pathological implications of large, synergistic networks of astrocytes have recently commanded more attention. Astrocytes can directly or indirectly communicate with hundreds of neighboring astrocytes via connexin protein-mediated gap junctions or nonsynaptic mechanisms. These large syncytia of astrocytes may operate in a coordinated fashion to increase the range and diversity of physiological and biochemical functions of the network (8) . For example, the capacity to buffer extracellular potassium is enhanced by spatial redistribution of potassium, absorbed at one part of the network, to astrocytes in other areas of the network with lower potassium concentration. Furthermore, physiological signaling may occur across extensive networks of astrocytes through gliotransmission or gap-junctionmediated communication. Glial calcium waves, a unique form of astrocytic signaling initiated by neurotransmitter-receptor activation, travel great distances along astrocyte networks in vitro, although it is not established whether they occur in vivo.
Despite recent insights into astrocyte network function under normal conditions, the mechanisms by which astrocyte networks influence epilepsy are poorly understood. Beyond the modulatory mechanisms of individual astrocytes that promote epileptogenesis, the collective properties of astrocyte networks likely add an extra level of complexity in regulating brain excitability in the epileptic state. Taking different approaches, the two papers reviewed here have investigated the role of astrocyte interactions in epilepsy; each focuses on separate structural organization and metabolic properties of astrocyte networks in epilepsy models.
The study by Oberheim et al. examined the structural interactions and overlap between astrocytes in the epileptic state. The study is based on the recent finding that cortical astrocytes are normally organized into unique spatial domains with minimal overlap of processes between neighboring astrocytes (9, 10) . This revelation emerged from advances in cellular imaging techniques that allow individual astrocytes and their processes to be visualized in their entirety. So, while astrocytes do communicate with each other extensively in large networks through gap junctions, these interactions normally occur in a limited portion at the periphery of astrocytic processes, with the majority of each astrocyte occupying its own unique territory. The functional implications of the nonoverlapping domains are not entirely clear, but a simple theory is that this organization permits individual astrocytes to compartmentalize physiological functions of large groups of neurons or synapses (each astrocyte domain may exclusively control over 100,000 synapses), thus exerting a more local measure of control or regulation across the larger area covered by astrocyte networks.
Oberheim et al. studied astrocyte domain organization in three different rodent models of epilepsy: the intracortical iron injection model of posttraumatic epilepsy, the pharmacological kainate epilepsy model, and an inbred genetic epilepsy strain. In each case, they observed typical signs of reactive astrocytosis in the cortex, with hypertrophy of processes and increased glial fibrillary acidic protein (GFAP) expression in astrocytes. More remarkably, based on diolistic labeling-a method for ballistically delivering membrane-adhering dyes to tissue to visualize individual cells in their entirety-there was a consistent loss of the nonoverlapping domain organization between neighboring astrocytes located around the epileptic focus. Compared to controls, the overlap of processes between adjacent astrocytes in epileptic animals increased by about 10-fold. The loss of domain organization was observed acutely within a week of the initial injury and persisted chronically over months. In contrast, in a genetic mouse model of Alzheimer's disease without seizures, cortical astrogliosis was prominent, as reflected by increased GFAP expression, but there was no significant hypertrophy or loss of domain organization of astrocytes.
Although these structural changes in astrocyte networks in epilepsy models are striking, their pathophysiological significance and consequences remain uncertain. The study by Oberheim and colleagues did not address the important issue of whether increased astrocytic overlap is causally involved in epileptogenesis. Suppression of seizures with valproate in the intracortical iron model partially prevented the loss of domain organization, indicating that seizures themselves, in part, cause the structural changes in astrocytes. However, this finding does not rule out the possibility that the astrocytic reorganization nonetheless contributes to an ongoing, progressive process of epileptogenesis. The study also showed correlative data of altered dendritic size and spine density of neurons that paralleled the astrocytic reorganization, but again, no cause-effect relationship was established. Future studies are needed to understand the specific implications and mechanisms of these findings, but it is attractive to speculate that the increased astrocytic overlap translates into abnormal connectivity and communication within astrocyte networks, which secondarily influences neurons to promote seizure generation.
In contrast to structural changes in astrocyte networks in epilepsy, the study by Rouach et al. focused on metabolic functions of astrocyte networks in regulating normal synaptic transmission and epileptiform activity. As glucose is the main fuel for neuronal activity, this study began by demonstrating that fluorescently labeled glucose (loaded into single perivascular astrocytes through a patch pipette) is transported extensively throughout astrocyte networks of hippocampal slices, delivering glucose from blood vessels to distant astrocytes and ultimately to neurons. The glucose trafficking through astrocyte networks was: 1) mediated by gap junctions (blocked by pharmacological or genetic antagonism of connexins) and 2) activity dependent (augmented by a zero magnesium solution and picrotoxin-induced epileptiform bursts). Remarkably, while glucose-free extracellular solution abolished epileptiform activity, intracellular glucose delivery to astrocyte networks partially restored epileptiform bursting of neurons despite extracellular glucose deprivation. These findings demonstrate a direct role for astrocyte networks in supporting epileptiform activity and suggest a novel approach for treating epilepsy by interrupting the metabolic communication of the networks. Inhibiting neuronal gap junctions is a proposed treatment for preventing seizure propagation between neurons; thus, blocking astrocyte gap junctions, similarly, may have an antiepileptic action. However, interrupting astrocyte communication also may have proconvulsant effects, such as impaired spatial potassium buffering. Although the two highlighted papers are significant in implicating astrocyte interactions in epilepsy, future studies are clearly needed to determine whether preventing collisions of the starlike cells in the brain may have benefits for epilepsy patients. protein (FMRP), but the pathogenesis of the disease is unknown. According to one proposal, many psychiatric and neurological symptoms of FXS result from unchecked activation of mGluR5, a metabotropic glutamate receptor. To test this idea we generated Fmr1 mutant mice with a 50% reduction in mGluR5 expression and studied a range of phenotypes with relevance to the human disorder. Our results demonstrate that mGluR5 contributes significantly to the pathogenesis of the disease, a finding that has significant therapeutic implications for fragile X and related developmental disorders. Here, we report that kindling increased the expressions of Fmr1 mRNA and protein in the forebrain of wild-type (WT) mice. Kindling development was dramatically accelerated in Fmr1 KO mice, and Fmr1 KO mice also displayed prolonged electrographic seizures during kindling and more severe mossy fiber sprouting after kindling. The accelerated rate of kindling was partially repressed by inhibiting N-methyl-D-aspartic acid receptor (NMDAR) with MK-801 or mGluR5 receptor with 2-methyl-6-(phenylethynyl)-pyridine (MPEP). The rate of kindling development in WT was not effected by MPEP, however, suggesting that FMRP normally suppresses epileptogenic signaling downstream of metabotropic glutamate receptors. Our findings reveal that FMRP plays a critical role in suppressing limbic epileptogenesis and predict that the enhanced susceptibility of patients with FXS to epilepsy is a direct consequence of the loss of an important homeostatic factor that mitigates vulnerability to excessive neuronal excitation.
Limbic Epileptogenesis in a Mouse

COMMENTARY
T he fragile X mental retardation protein (FMRP) is an intracellular RNA-binding protein that serves to repress mRNA translation. It is widely expressed in many tissues but particularly abundant in the brain, especially in dendrites at glutamatergic synapses. Despite its name, this protein actually is absent in patients with fragile X syndrome, a condition that is the result of an inappropriate CGG trinucleotide repeat expansion of FMR1-the X-linked gene in humans that encodes the synthesis of FMRP. The phenotype of the Fmr1 knockout mouse approximates well the human condition: memory deficits and learning difficulties, autism and epilepsy, altered body growth and macroorchidism are all features common to both. Similarly, neuropathological and electrophysiological studies have yielded analogous results in fragile X syndrome patients and knockout mice, revealing an abnormal abundance of immature long, thin dendritic spines in cortical neurons accompanied by aberrant synaptic plasticity (1, 2) .
How does the absence of FMRP result in this constellation of phenotypic abnormalities? FMRP is generally viewed as a protein synthesis inhibitor, targeting multiple dendritic mRNAs to suppress their translation. Localized dendritic protein synthesis is a key requirement for the induction of long-term, activitydependent synaptic plasticity, which is the fundamental physiologic mechanism for learning and memory and likely, an essential contributor to epileptogenesis (3) . Nearly all the mRNAs that have been validated as targets for FMRP have been shown to be regulated by activation of group I metabotropic glutamate receptors (mGluRs) at some level (e.g., mRNA stability, dendritic transport, local translation, or protein expression) (4) . Under normal conditions, group I mGluR activation will stimulate translation of FMRP target mRNAs and simultaneously will trigger ubiquitination and degradation of FMRP to de-repress these mRNA targets and allow, to some extent, induced protein synthesis to occur (5). However, should this mGluR-induced protein synthesis be allowed to take place unchecked, as would occur in the total absence of FMRP, severe sequelae may ensue, as demonstrated by the constellation of abnormalities seen in fragile X syndrome.
To test the hypothesis that fragile X syndrome is primarily the result of exaggerated group I mGluR-driven responses, Dölen and colleagues created a mouse that was crossbred to coexpress two genetic mutations, resulting in simultaneous absence of FMRP and 50% reduction in expression of mGluR5, a member of the group I mGluR family. They compared the behavior, anatomy, and physiology of this novel mutant mouse Epilepsy Currents, Vol. 9, No. 4 ( July/August) 2009 pp. 116-118 Wiley Periodicals, Inc. C American Epilepsy Society to wild-type mice and to Fmr1 knockout mice (i.e., lacking FMRP but with normal mGluRs). The authors performed an impressive array of experiments, testing synaptic plasticity in visual cortex, behavioral memory, audiogenic seizure susceptibility, dendritic spine density, basal protein synthesis in hippocampus, and prepubescent body growth-all of which are abnormal in the fragile X syndrome mouse model. Their findings demonstrated that each of these abnormalities was restored to control values in the fragile X hybrid with reduced mGluR5 expression, thereby, strongly validating the hypothesis. The only feature that was not rescued by the reduction of mGluR5 was macroorchidism: even when mGluR5 expression was completely eliminated, macroorchidism still appeared, suggesting a different mechanism for this phenotypic derangement (possibly driven by mGluR1, the other member of the group I mGluR family).
These data are remarkable, as they clarify the underlying mGluR-dependent pathogenesis of the disturbances expressed in fragile X syndrome. However, reversal of the phenotype in these experiments required reducing mGluR expression from the moment of conception. So, it still begs the question: how much benefit can blockade of mGluR5 provide after birth and development have taken place? Notably, mGluR5 antagonists do continue to provide therapeutic relief in fragile X syndrome patients, as shown by the suppressive effect of these agents on both seizures and behavioral abnormalities (6) .
Rather than look at spontaneous or audiogenic seizures in fragile X syndrome as others had already done, Qiu and colleagues examined the development of kindling-induced seizures in the fragile X knockout mouse to determine whether there is a difference in epileptogenic propensity. Their control experiments, examining Fmr1 mRNA and FMRP expression in kindled versus unkindled wild-type mice were not always substantiated, with many claims followed by the statement "data not shown." Nevertheless, subsequent experiments in which the investigators compared kindling in wild-type and fragile X syndrome mice provide results with far-reaching implications.
When compared with wild-type animals, the knockout mice demonstrated a lower threshold for kindling. The mice expressed more robust seizures in response to fewer stimuli, which correlated with more severe mossy fiber sprouting on pathological examination. Although NMDA receptor antagonists could slow the progression of kindling in both control and knockout animals, only the fragile X mice were helped by MPEP, an mGluR5 antagonist. Hence, it appears that the enhanced sensitivity to kindling in the fragile X mice may be mediated by increased activation of mGluR5 or more robust downstream effects. These data suggest that exaggerated mGluR5 responsiveness may contribute to a predisposition for the development of epilepsy in this condition. The lowered threshold for the expression of robust seizures is consistent with studies performed in hippocampal slices in which application of GABA A receptor antagonist, an agent that typically elicits only interictal discharges in control mice, evoked seizure-length discharges in Fmr1 knockout mice, which could be suppressed with mGluR5 blockers (7, 8) .
Hence, in the case of mGluR-induced epileptogenesis, there appears to be a delicate balance between a potentially epileptogenic protein synthesized by mGluR5 activation and FMRP. In the normal neuronal network, Qiu et al. demonstrate that FMRP can limit the progression of epileptogenesis by preventing mGluR5 activation from playing a significant part in the process. However, it has also been shown that sufficient activation of mGluR5 can overcome the endogenous FMRP-mediated protection and elicit a long-lasting protein synthesis-driven enhancement of group I mGluRmediated excitation in the hippocampal network, resulting in the persistent expression of seizure discharges (i.e., epileptogenesis) (9-11). Both Qiu and Dölen have shown that the converse is true as well: in the absence of FMRP, epileptogenesis is accelerated via enhanced mGluR5 participation; and, reduction of mGluR5 activation can compensate for the lack of FMRP in the fragile X mouse, restoring a near-normal phenotype.
The findings reported in these fragile X syndrome studies may have broad implications for the understanding of epileptogenic mechanisms in humans. Clinicians frequently encounter epileptogenesis in victims of head trauma or cortical strokes, for which there is typically a latency between the original insult and the onset of clinical seizures. One of the difficulties in the management of these patients is an inability to predict which patients will go on to develop epilepsy. It is logical to propose that the susceptibility to posttraumatic or poststroke epilepsy may be in part determined by the patient's endogenous level of FMRP expression or mGluR excitability. There are also different isoforms of FMRP whose functions as yet are undetermined. Perhaps, advances in genetic testing for variations in these molecules and their activity may one day allow targeted pharmacological therapies for those patients at greatest risk. These are exciting times for translational research in this arena; it may be that the development of truly antiepileptogenic therapies is finally within reach. 
by Lisa R. Merlin, MD
LEUKOCYTE-ENDOTHELIAL ADHESION MECHANISMS IN EPILEPSY: CHEERS AND JEERS
A Role for Leukocyte-Endothelial Adhesion Mechanisms in
COMMENTARY
A flurry of recent papers has convincingly demonstrated that inflammation, blood-brain barrier (BBB) leakage, and seizures are etiologically linked. In human subjects and animal models, it was shown that cerebrovascular or inflammatory events can actually cause seizures (1,2) . Accordingly, the study by Fabene et al. established that brain inflammation and BBB disruption are realistic triggers of seizures in a mouse model of status epilepticus.
There is substantial evidence supporting both CNS and intravascular inflammation as being seizure promoting or proepileptogenic. BBB damage is known to directly cause seizures (3, 4) and to increase spontaneous seizure frequency (5). Blockade of CNS or systemic inflammation pathways (e.g., via inhibition of interleukin [IL]-1β signaling with IL1-receptor antagonist or via blockade of IL-1β production with caspase-1 inhibitors) reduces status epilepticus and seizure frequency (6, (7) (8) (9) . Glia, neurons, and endothelial cells express cytokines following seizures in experimental models (10) , in human epileptogenic tissue (10) (11) (12) , and after brain injury (13) . These findings point to a prominent role for cytokines in the pathogenesis of seizures. Elucidation of the mechanisms Epilepsy Currents, Vol. 9, No. 4 ( July/August) 2009 pp. 118-121 Wiley Periodicals, Inc. C American Epilepsy Society underlying the effects of cytokines in seizures highlights nonconventional modes of action involving direct effects on neuronal excitability (14-16) or a direct action on BBB integrity (3, 9, 17) . Taken together, these findings establish a novel concept: altered brain function may result from parenchymal or extraparenchymal inflammatory signals, acting in concert or alone.
To shed light on the mechanisms by which BBB leakage may occur, Fabene and colleagues set out to test whether leukocyte-endothelial cell interactions are altered by seizures and whether they can, in turn, contribute to BBB leakage, seizure pathogenesis, and epilepsy. As occurred in the work by Marchi et al. (9, 17) , Fabene et al. focused mainly on peripheral inflammation using a mouse model of pilocarpine-induced status epilepticus, evolving to spontaneous seizures.
After the pilocarpine administration, endothelial cell activation was studied. Results showed vascular induction of leukocyte adhesion molecules, which are expressed at low levels under physiological conditions. Specific adhesion molecules reached their highest levels of expression within 1 week after pilocarpine challenge; the earliest time point at which induction was studied was 6 hours after the onset of seizures. The authors concluded that seizures induce the adhesion of circulating lymphocytes by upregulation of adhesion molecules.
A note of caution: the possibility of a direct effect of pilocarpine on leukocyte-vasculature interactions cannot be ruled out, as suggested by the significant upregulation of vascular cell adhesion molecule-1 (VCAM-1), even when status epilepticus was prevented pharmacologically. In this regard, recent evidence indicates that pilocarpine has a direct proinflammatory effect when endothelial and white blood cells (WBCs) are exposed to this drug in vitro, leading to production and release of IL-1β. This effect was confirmed using convulsant doses of pilocarpine, which when used in vivo induced elevated levels of serum IL-1β (17) . Since these proinflammatory actions of pilocarpine in vivo occur shortly after drug injection and before the onset of status epilepticus, the possibility that the initial trigger of microvascular activation and consequent upregulation of adhesion molecules stems from pilocarpine itself should be considered.
In a second set of experiments, the authors report that leukocytes exposed to pilocarpine in vitro do not show increased expression of VCAM-1 receptors. However, this evidence does not exclude the fact that pilocarpine in vivo could enhance VCAM-1 expression in endothelial cells via IL-1β release by WBCs, with corresponding increased leukocyte adhesion (17) . It is well known that IL-1β is a strong inducer of endothelial adhesion molecules (18, 19) . We can, therefore, envisage that the activation of WBCs by pilocarpine leads to a cascade of events causing the release of IL-1β and consequent changes in BBB permeability; these effects synergistically potentiate direct CNS action of pilocarpine, leading to seizures (9, 17) . The requirement of BBB opening for pilocarpine proconvulsant effects was recently demonstrated by Uva et al. (20) .
In a subsequent set of experiments that used the same pilocarpine model, Fabene et al. asked whether leukocyte adhesion contributes to status epilepticus. They showed prevention of status epilepticus in wild-type mice pretreated with an anti-α4-integrin antibody, which hampers the adhesion of leukocytes to VCAM-1 on endothelium. Since these adhesion molecules are only minimally expressed in naive mice and given the fact that the antibody cannot act in the absence of its target protein, these results indicate that VCAM-1 is likely upregulated before the onset of status epilepticus, possibly by pilocarpine itself. Thus, using this study protocol, the authors might have blocked or reduced status epilepticus (and, thus, neuropathology and epilepsy in mice) by preventing the mechanism by which pilocarpine can exert its convulsant action. To shed light on whether leukocyte adhesion is a specific mechanism associated with pilocarpine use, it will be crucial to evaluate adhesion molecule expression before the onset of pilocarpine-induced status epilepticus and to extend these results to other models of status epilepticus. In addition, it will be valuable to assess the seizure threshold after blockade of endothelial adhesion mechanisms. Such investigations would allow the sorting out of the contribution of adhesion mechanisms in the generation or prevention of seizures.
Fabene et al. asked whether leukocyte adhesion contributes to epileptogenesis. They induced status epilepticus for 1 hour, and then chronically treated mice with antibodies against adhesion molecules every other day for 20 days. The investigators found no effect of these treatments on acute status epilepticus, as reported for α4 integrin-specific antibody, but there was a significant reduction of daily spontaneous seizures 20 days poststatus epilepticus, with no effect on timing of seizure onset or duration.
This interesting result supports previous findings showing that microvasculature alterations induced by status epilepticus and leading to BBB opening, significantly contribute to sustained hyperexcitability underlying spontaneous seizures (3, 5, 9, 17, 21) . Previous evidence has also shown that when sustained seizure activity is induced in guinea-pig-isolated and CSF-perfused brain preparations, it stimulates expression of endothelial adhesion molecules (22) . The induction of these molecules by seizures in the isolated brain may have been triggered by inflammatory reactions involving cytokines produced by perivascular astrocytes during epileptic activity (10) . Once again, the effect of in vivo antiadhesion strategy, after status epilepticus, needs to be confirmed in a model of seizures in which the primary convulsant stimulus has no direct peripheral proinflammatory actions to exclude the possible synergy between these peripheral effects and the effect of seizures in determining the pathological outcome.
Finally, Fabene et al. evaluated a population of human subjects to show that adhesion/extravasation of leukocytes is more commonly observed in epileptic patients than control subjects. The epileptic population studied consisted of postmortem autopsy samples derived from subjects with comorbidities ranging from hepatic failure to cardiac arrest, both known to lead to rapid disintegration of the BBB (2). It is, however, surprising that control subjects were devoid of WBC extravasation, given that the stated causes of death were ischemic in nature in eight of ten samples, as it is well known that brief ischemia or even normoxic-normoglycemic flow cessation cause inflammatory changes, leading to leukocyte adhesion and BBB disruption (2) .
The relative epileptogenic contribution of inflammatory reactions intrinsic to the brain compared with those mediated by peripheral immune cells remains to be established. Unquestionably, BBB failure is the link between these two mechanisms. Human pathology studies show pronounced parenchymal cell expression of inflammatory markers, including IL-1β, cyclooxygenase-2 (COX-2), and complement factors, in all brain specimens evaluated so far for epilepsies of different etiologies (11, 12, 23, 24) . However, evidence for prominent recruitment of leukocytes in epileptogenic tissue has been reported in some epilepsies, such as tuberous sclerosis (12) and Rasmussen's encephalitis (25) , but not in others, such as temporal lobe epilepsy (10) .
In summary, this study reveals an interesting overlap among diseases associated with white matter, such as multiple sclerosis and epilepsy. Thus, it highlights the possibility that WBC interactions with brain vasculature, in the context of preexisting systemic inflammation, contribute to the pathogenesis of seizures, via disruption of BBB. The therapeutic potential of antiadhesion molecules to reduce the severity of epilepsy when administered after a period of status epilepticus is an attractive novel strategy. Similar antiepileptogenic effects from systemic treatments with α2-adrenoceptor antagonist, atipamezol (26) , diazepam (27) , and fluorofelbamate (28) significantly decreased the frequency of spontaneous recurrent seizures or their severity and afforded neuronal protection. Further elucidation of these mechanisms in additional clinically relevant experimental models is important, since this knowledge may open new therapeutic perspectives for seizures and epileptogenesis using anti-inflammatory drugs directed against parenchymal or peripheral inflammation that are already available for autoimmune chronic inflammatory diseases. This finding is supported by the recently reported effects of steroids in pediatric epilepsy (29) .
by Annamaria Vezzani, PhD, and Damir Janigro, PhD et al. takes on these issues by exploring the dysregulation of T-type Ca 2+ (Ca v 3.2) channel expression after status epilepticus. This impressive study provides compelling evidence for a proepileptic effect of Ca v 3.2 channels and challenges common assumptions of how acquired ion channelopathy may produce epilepsy.
T-type Ca 2+ channels have long been implicated in epilepsy. Their biophysical characteristics of low activation voltage, rapid kinetics, and voltage-dependent inactivation yield transient depolarizing currents that predispose neurons to burst firing. Their enriched distribution in the dendrites of pyramidal neurons places them in the company of other intrinsic conductances, such as A-type K + channels and hyperpolarizationactivated cation channels, which also are dynamically regulated in epilepsy (2, 3) . Previous work has shown up-regulation of T-channels in CA1 pyramidal neurons occurs in chronic epilepsy (4), T-channels mediate thalamocortical bursting phenomena underlying generalized seizures (5) , and inhibition of these channels by ethosuximide likely mediates the drug's antiepileptic effect in absence epilepsy (6) . The present study by Becker and colleagues analyzes in great detail the regulation of T-channels in CA1 pyramidal neurons following an episode of pilocarpine-induced status epilepticus (the sheer scope of the methodology of this study, filling two and a half published pages of Methods, alone is impressive). The authors begin by demonstrating that a single subtype of T-channel, Ca v 3.2, underwent transient transcriptional upregulation, beginning within 2 days after induced status epilepticus and terminating by day 10. By day 5 post-status epilepticus, protein expression of Ca v 3.2 increased five-fold; this effect too returned to normal levels a month later. Bursting behavior of CA1 neurons followed Ca v 3.2 levels, with a transient increase in the proportion of cells able to produce action potential bursts that returned to normal levels 20 days after status epilepticus. Importantly, mice with genetic deletions of the Ca v 3.2 subunit did not show the up-regulation of bursting behavior, proving its dependence on this subtype of T-channels. an increase in severity of the epilepsy phenotype. The objection could be raised that the knockout animals may have experienced a reduced intensity of provoked status epilepticus, which would in turn, have led to a milder epileptic condition. However, the authors quantified the status epilepticus duration and EEG spectrum intensity to show this was not the case.
In several ways, these findings challenge current conceptions of ion channelopathy in acquired epilepsy. The notion that ion-channel expression may transiently change, yet produce long-lasting epilepsy results, is contrary to the assumption that ion channelopathy occurs early and is persistent. Also, the specificity of these findings to a single ion channel subtype, while other subtypes mediating similar currents remain unchanged, is puzzling. So, does Ca v 3.2 mediate epileptogenesis? In the strict sense of the term, the answer is unclear. Ca v 3.2 knockouts ultimately develop epilepsy, just as wild types do, and with a similar time course. Thus, it does not appear that Ca v 3.2 deletion inhibits or delays the development of epilepsy. Because Ca v 3.2 channels are constitutively deleted in the knockouts, we cannot exclude the confounding possibility that these channels are exerting an antiepileptic-not antiepileptogeniceffect on seizure frequency and other neurodegenerative markers of epilepsy. Of note, the T-channel blocker ethosuximide does not produce significant antiepileptic actions in human acquired epilepsy syndromes, which may argue against this theory.
The authors acknowledge that development of a conditional knockout for Ca v 3.2 channels could address these issues by allowing transient suppression of Ca v 3.2 expression to occur only during the key post-status epilepticus period, while maintaining normal levels during epilepsy induction and chronic epilepsy. Such a difficult experiment would add important additional proof that Ca v 3.2 channels mediate epileptogenic neuronal plasticity, without producing antiepileptic actions as well.
Despite these limitations, the present study is one of the most complete descriptions of an acquired channelopathy in an animal model of epilepsy, tracing the development of Ca v 3.2 up-regulation from gene to protein to neuron to behavior. The thoroughness of the work by Becker et al. sets a new standard for studies of channelopathy and acquired epilepsy. Given the variety of ion channel alterations that already have been described, it is unrealistic to think that acquired epileptogenesis will depend on a single channel subtype, as it does in some human genetic syndromes. However, this study demonstrates that alteration of one ion channel species can have dramatic effects on the expression of chronic epilepsy. Further work to understand what early events link neural insults with subsequent derangement of channel expression and function may uncover common mechanisms of epileptogenesis that could be used to therapeutically target true preventative measures against epilepsy.
by Nicholas P. Poolos, MD, PhD
